AZN Articles, AstraZeneca PLC - From 12/20/23

COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023. ...

Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody prog...

Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct compreh...

AstraZeneca (NASDAQ:AZN) has announced an acquisition of Icosavax (NASDAQ:ICVX) that is expected to be completed in Q1 of 2024. Under the terms of ...

AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Icosavax Inc (NASDAQ: ICVX) at $15.00 per share in cash at closing, plus a non-t...

Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy o...

The White House is endorsing a contentious power that permits the government to reclaim patents for specific high-cost medications.&...

AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDA...

European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, includ...

AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE-CKD and DIALIZE-Outcomes Phase 3 evidence trials for Lokelma (sod...